

19 October 2023

Company Announcements Office
Australian Securities Exchange

Breathe Life Sciences (BLS) Builds Australian Medicinal Cannabis Business

Highlights

- **BLS has imported a further 200kg of premium high THC cannabis flower worth ~\$3.2m**
- **First to import cannabis flower from the UK, world's biggest producer and exporter of cannabis for medicinal and scientific purposes**
- **GMP inspection date confirmed (November) to scale pharmaceutical production capability for Australian, UK, and German markets.**

Bioxyne Limited (ASX: BXN) (Bioxyne or Company) is pleased to advise that its wholly-owned subsidiary Breathe Life Sciences (BLS) has recently imported and irradiated a further 200kg of premium high THC cannabis flower across four strains into Australia, with a dispensed patient value of \$3.2 million as it works to build in its presence in the Australian market.

BLS is the first Australian company to import cannabis from the UK with 100kg of its latest import coming from the world's biggest producer and exporter of legal cannabis for medical and scientific purposes. The product will be packed into the Company's Dr Watson™ brand and sold via special access pathways and supplied as bulk product to compounding pharmacies and licensed manufacturers.

In Australia, BLS holds licenses to import, export, wholesale Schedule 3, 4, and 8 controlled substances including medicinal cannabis, ketamine, and psilocybin and MDMA following TGA rescheduling in July of this year. The company's licences allow it to import, store, and distribute these unregistered medicines via approved pathways, facilitating [online patient consultations](#) with authorised prescribers for Australian patients to access to these alternative medicines.

The company has a drug development pipeline which includes Psilocybin (magic mushrooms) and MDMA capsules and expects to have established commercial pathways via clinical trials and authorised prescribers in 2024.

BLS has confirmed with the TGA a day in November for GMP inspection, audit, and certification of its Brisbane pharmaceutical GMP manufacturing facility, allowing it to scale production capabilities significantly.

Sam Watson, BXN CEO, commented " *GMP certification will allow a significant scale up of production, which will supply both Australian and foreign markets, including Germany, Czech Republic, and the UK where BLS have a strong foothold and sales team. We are seeing tremendous growth in our pharmaceutical business here. Medicinal cannabis in Australia is fast approaching a billion dollar industry, and we are going to be a big part of that. This has already benefitted our international operations and sales teams in the UK, Europe, and Japan.*"

This announcement has been approved for release to the ASX by the Board.

For further information contact:

Sam Watson
Managing Director
Bioxyne Limited
sam@breathelifesciences.com

Guy Robertson
Chief Financial Officer
Bioxyne Limited
guy@bioxyne.com

About Bioxyne

Bioxyne Limited (ASX:BXN) is an international Australian life sciences company headquartered in Sydney, and parent company of the Breathe Life Sciences Group. Bioxyne and wholly owned subsidiary [Breathe Life Sciences](#) manufacture and distribute consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines. In Australia, Breathe Life Sciences holds controlled substance licenses to import, export, wholesale and manufacture Schedule 3,4 and 8 poisons (Medicinal cannabis), operating a wholesale distribution model as well as direct to patient supply of prescribed medications via telemedicine platform [BLS Clinics](#). Outside of Australia, the business has manufacturing and distribution centres in Japan, the UK, and Europe, and operates direct to consumer supply of its trademarked [Dr Watson](#)[®] brand.

For more information on Bioxyne, please visit <https://bioxyne.com>